Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
about
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylationCyclin-dependent kinase inhibitor therapy for hematologic malignanciesChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsTargeting Mcl-1 for the therapy of cancerComparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype SelectivitySubstituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesThe novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoPhase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.8-Amino-adenosine inhibits multiple mechanisms of transcription.Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinomaImpact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single centerPotent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.Potential of plant-derived natural products in the treatment of leukemia and lymphomaTargeting MET transcription as a therapeutic strategy in multiple myeloma.Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioA phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridolProtein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskLycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.The history and future of targeting cyclin-dependent kinases in cancer therapy.Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin EHigher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.Molecular targeted approaches in mantle cell lymphoma.
P2860
Q24323313-DB9B4EB1-ECDD-4DF5-9C00-398006C2B260Q24561485-735E1225-D600-4977-A368-0B1376BD0577Q26764833-D71F996D-62C0-4BCF-B07A-CA77D4D44A43Q27011870-2E012A75-3195-40DE-A731-3F76FFC55CE1Q27675539-03DF0A5D-1669-490D-834A-8D33A58CBBDEQ27675842-33FE850F-0A17-4763-9BB3-68FF858B0421Q28751751-46E7CE01-B709-4CD7-8AAB-CADDFD0C7732Q33386193-242C4BF9-66FE-4415-B9D9-B5F9500B3790Q33394689-E4F0197C-63B4-4442-913F-4BEFF0265952Q33396918-4A322B08-42AF-4CE0-96E2-27EABE25EB94Q33409459-EB590DE6-D856-46BB-B094-AA15DED5FB74Q33417803-8A6F84F7-2C1C-4B3D-B889-87E04CE135CDQ33440533-11288221-2854-414F-9216-82CC0433D898Q33590629-7C4595B0-8E0D-442A-948D-500A72B85E74Q33627721-1F6C16F1-CB1C-4C83-BD02-2746331FFC9AQ33638819-EF3B03DD-CB33-4AB2-A554-F4B557443EFDQ33709855-5A3A7FF7-04C5-421F-93CE-01ABCAB4D440Q33717615-BC216E5D-5EFF-4481-BE9F-32FE44E75054Q33751778-8F471047-8EDB-4D06-B0CF-DBB58017F68AQ33806087-24AD3761-84EA-44FF-BEBF-3A75A7A6357BQ33872754-17F8AAB8-B6FC-485B-93CA-F4EB91DD78D0Q33942845-5B15C6F3-0486-4A6A-8E37-EFB24E2670A8Q33943962-84C02B83-A67D-4B9B-B414-B3812525279AQ33952759-9DE5D1CA-B9B5-4DEC-8162-EDA62895D0B6Q34038766-C6B920C9-4F35-4259-BDB9-BA322CD06C86Q34114592-4D1BFED8-888D-45A2-9512-6D1B441C054EQ34195072-4E7F402C-0DF3-49CB-8763-4C602D9F4FA6Q34202277-CDE3DE32-9927-4F66-8446-654A82C4B627Q34214083-3DE25057-C486-4A96-A6F6-ABBAFD5FD89AQ34255118-0DBDDF74-CDB5-4557-AF22-31C49F569C8FQ34255124-F7673FE6-1CC0-4C25-9D4B-D14967ED6DB7Q34334943-2C56A60E-F744-4091-AB1B-3A18E91216B2Q34365839-E003E38F-8A89-4669-AD67-DE68F211543AQ34458745-6F9A3653-6CEA-42DE-AEDD-5D858632971EQ34460347-C6D99A28-81AA-4DFE-AB1B-6B28EE4FA425Q34754350-BFB939E2-D40F-4293-8EA3-4BEBAD57BB46Q34777365-765E01CA-2036-4C6F-9785-5E777B85D096Q34901237-BB823316-4B3D-4E5A-A568-FDF0FF0C14F5Q35033514-AA57AB6F-5A8A-4778-8E9F-7C64F39646EEQ35127368-61B6CB58-4AE1-40D4-A612-9D31A1F90FE7
P2860
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Flavopiridol administered usin ...... k chronic lymphocytic leukemia
@ast
Flavopiridol administered usin ...... k chronic lymphocytic leukemia
@en
type
label
Flavopiridol administered usin ...... k chronic lymphocytic leukemia
@ast
Flavopiridol administered usin ...... k chronic lymphocytic leukemia
@en
prefLabel
Flavopiridol administered usin ...... k chronic lymphocytic leukemia
@ast
Flavopiridol administered usin ...... k chronic lymphocytic leukemia
@en
P2093
P2860
P50
P1433
P1476
Flavopiridol administered usin ...... k chronic lymphocytic leukemia
@en
P2093
A Dimitrios Colevas
Amy J Johnson
Beth Fischer
Brad Rovin
David M Lucas
Donn C Young
Gerard Lozanski
James T Dalton
Jose-Ramon Suarez
P2860
P304
P356
10.1182/BLOOD-2006-05-020735
P407
P577
2006-09-26T00:00:00Z